Polyclonal antibodies to synthetic human pancreatic growth hormone-releasing factor )NH2] and rat hypothalamic growth hormone-releasing factor [rhGRF(1-43)OHJ were produced in rabbits by injecting these weak immunogens, coupled to thyroglobulin and emulsified with complete Freund's adjuvant in the presence of activated charcoal, directly into the spleen. A subsequent booster in-jection by the conventional intramuscular route resulted in high-titer antibodies, which at a 1:20,000 dilution were used to develop highly sensitive and specific radioinmunoassays for these peptides. By using antibodies with an apparent K. of 3.3
Since 1959 (1) , it has been known that the hypothalamus is involved in the control of growth hormone (GH) secretion. Experimental and clinical evidence has since indicated that the hypothalamus performs a dual function in the regulation of GH secretion from the anterior pituitary (2) (3) (4) . Inhibition of GH release is accomplished by an inhibitory peptide, somatostatin (SRIF), which in 1972 was isolated from ovine hypothalami, purified, and characterized as a tetradecapeptide (5) . In contrast, as suggested by physiological evidence (2) (3) (4) and GH-releasing activity in hypothalamic extracts (6) (7) (8) , stimulation of GH release is accomplished by a stimulatory peptide, GH-releasing factor (GRF). Until 1982, however, the isolation and characterization of GRF remained elusive. The difficulty in its characterization had been due to the minute quantities of the peptide in hypothalamic tissue, the large quantities of SRIF that interfere in the bioassay, and the fact that the methodology used for peptide sequencing and purification has only recently become available (9) (10) (11) (12) .
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Many investigators have reported the presence of GH-releasing activity in human carcinoid tumors (13) (14) (15) and pancreatic islet cell tumors removed from patients with acromegaly (15) (16) (17) . Recently, human pancreatic GRF (hpGRF) was isolated and structurally characterized from two pancreatic islet cell tumors in patients with acromegaly (9, 18, 19) . In one tumor, only a 40-amino acid peptide was isolated (18, 19) , while the other tumor was found to contain three peptides consisting of 37, 40, and 44 amino acids (9) , of which the 40-amino acid peptide was the major component. Recent evidence indicates that human hypothalamic GRF is identical to the 44-amino acid COOH-terminal amidated hpGkF (refs. 12, 20; *) . Hypothalamic GRF has been characterized in many species-porcine (21) , bovine (22) , and ovine (12)-as 44-amino acid COOH-terminal amidated peptides with <5% amino acid substitution from hpGRF(1-44)NH2.* Spiess et al. (23) have reported that rat hypothalamic GRF (rhGRF) is a 43-amino acid NH2-terminal histidine, COOHterminal free acid polypeptide, with a 67% homology with hpGRF(1-44)NH2. These GH-releasing peptides have a close structural homology with the glucagon-secretin family, especially PHI-27 (18, (23) (24) (25) .
Both native and synthetic GRF peptides have been shown to be specific and potent stimulators of GH secretion from the anterior pituitary in vitro and in vivo (9, 18, 26, 27) . In addition, the NH2-terminal 29 amino acids of hpGRF maintain full intrinsic activity and potency in vitro (18) , and recently amino acids [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] tion was stirred on a rotary mixer for 1 hr at room temperature, then dialyzed in spectapor 3 membrane tubing (Spectrum Medical Industries, Los Angeles) against a 1-liter 10 mM phosphate buffer (pH 7.4) for 2 hr at room temperature with constant stirring. The dialyzed complexes were emulsified with complete Freund's adjuvant (GIBCO) and normal saline (1:1:1) in the presence of 10 mg of active charcoal (Fisher), using two glass syringes connected by a three-way stopcock until the emulsion was firm.
Immunization. Female New Zealand White rabbits (Hazelton Dutchland, Denver, PA) were immunized with one of the complexes by the following procedure: The rabbits were anesthetized with sodium pentobarbitol and atropine sulfate.
The skin overlying the region of the spleen was shaved, sterilized with betadine solution, and anesthetized with 2% lidocaine containing epinephrine (1:100,000). A left lateral incision was made and the spleen was exposed and injected with a total of 450 ,1 of the freshly conjugated peptide/thyroglobulin/Freund's adjuvant emulsion (150 jxg of peptide). The incision was then closed in a layered fashion. Two weeks after the initial immunization, the rabbits were given intramuscular booster injections of 1 ml of the complex (100 gg of peptide) in the presence of incomplete Freund's adjuvant. At 1-to 2-week intervals, blood was collected from the ear vein and the serum was examined for the presence of antibodies. When a consistent decline in antibody titer was observed, intramuscular booster injections were repeated.
Radioimmunoassays. Iodination. A modification of the Greenwood and Hunter chloramine-T method (28) was used to label hpGRF(1-44)NH2 and rhGRH(1-43)OH with 1251 (Amersham). At 40C, the iodination of both peptides was carried out by the successive addition of phosphate buffer (pH 7.5; 250 mM; 20 ul), hpGRF(1-44)NH2 or rhGRF(1-43)OH (500 ,ug/ml in 0.005 M HCl; 10 IlI), 1251 (500 ,uCi; 1 Ci = 37 GBq) and chloramine-T (5.25 mg/ml; 10 ,u; Kodak). The reaction was terminated 10 sec later by the addition of sodium metabisulfite (4.8 mg/ml; 20 ,ud; Fisher) and 500 ,u1 of human serum albumin (0.1%; Sigma) in acetic acid (100 mM; Fisher). The labeled antigen was purified on a Sephadex G-50 fine column (1 x 50 cm; Pharmacia) and eluted with 0.1% human serum albumin in 100 mM acetic acid. Prior to usage in the radioimmunoassay, the labeled antigen was repurified on Quso G-32 (29) .
Competition between antigen and antibody. One hundred microliters of standard, hpGRF(1-44)NH2 or rhGRF(1-43)OH, 100 ,ul of their corresponding antiserum at a final dilution of 1:20,000, and 100-,ul aliquots of unknown samples were mixed together and the final volume was adjusted to 400 pA with the assay diluent (19 mM NaH2PO4, monobasic/81 mM Na2HPO4, dibasic/0.1% bovine serum albumin/0.05 M NaCl/0.01% sodium azide/0.1% Triton X-100, pH 7.5). After 48 hr of incubation at 4°C, 100 pl (5000 cpm) of radiolabeled hpGRF(1-44)NH2 was added. When rhGRF(1-43)OH was used for competition, 100 ul (2500 cpm) of radiolabeled rhGRF(1-43)OH was added after 24 hr of cold incubation. The antigen-antibody complex of hpGRF(1-44)NH2 was separated from the free antigen after 5 days of cold incubation; in the case of rhGRF(1-43)OH, the separation was performed after 2-3 days of cold incubation. The separation was performed by adding 1 ml of diluent and 1 ml of dextran-coated charcoal (2.5 mg of charcoal and 0.25 mg of dextran T-70) per tube. After centrifugation at 4500 x g for 15 min, the pellet and supernatant were separated and counted in an automatic y counter for 3 min. Each standard or unknown was assayed in duplicate.
Titration of Antibody. The individual antibodies were serially diluted in assay diluent to a working dilution of one-fifth the desired final dilution, and 100 Al of each antibody dilution was added to test tubes containing 300 pA of assay diluent. Radiolabeled hpGRF(1-44)NH2 (5000 cpm per 100 A1) was added to the appropriate antibody tubes after 48 hr of cold incubation; radiolabeled rhGRF(1-43)OH (2500 cpm per 100 /l) was added after 24 hr of cold incubation. After incubation at 40C for 5 days for hpGRF(1-44)NH2 and for 3 days for rhGRF(1-43)OH, the antigen-antibody complex was separated from the free antigen by dextran-coated charcoal as described. The bound-to-free (B/F) values were calculated and plotted against the corresponding antibody dilution. The affinity constant (Ka) for each titration curve was determined according to the method of Frazier and Rodbard (30) .
Tissue Extraction. Rat hypothalami were obtained from adult male Sprague-Dawley rats (200-250 g) (Taconic Farms, Germantown, NY) immediately after decapitation and were kept at -20'C. Mouse and guinea pig hypothalami were collected in the same manner from 56-to 70-day-old male BALB/c mice (Charles River Breeding Laboratories) and young adult male Hartley white guinea pigs (400-500 g) (Camm Research Institute, Black Oak Ridge, NJ). Bovine and ovine hypothalami were obtained as freshly frozen tissue (Pel-Freeze) and human hypothalami were obtained in the course of autopsy examination of healthy male individuals 6-12 hr after accidental death. Tissues from all specimens were homogenized with distilled water at a concentration of 100 mg of tissue per ml of water. The homogenized suspension was then heat-treated in a boiling water bath for 10 min, chilled at 40C, and centrifuged at 12,400 x g at 40C for 30 min to separate the precipitated proteins. The resultant supernatants were stored frozen for 1-2 weeks until assay. At the time of assay, the supernatants were thawed and serial dilutions were made. Samples of each dilution (100 IlI)
were assayed in duplicate according to the previously outlined radioimmunoassay procedure.
Ontogeny Study. Two-day-old male Sprague-Dawley rats (Charles River Breeding Laboratories) were housed at a constant ambient temperature (22 ± 1°C) and humidity conditions on a 12-hr-light/12-hr-dark cycle. For the first 22 days, nutrition was provided by a foster mother (10 rats per mother); thereafter food (Purina rat chow) and water were provided ad lib. At 2, 4, 8, and 16 weeks of age, the rats were sacrificed at 10:00 am by decapitation. Brains were removed, placed immediately on dry ice, and then stored for 1-2 weeks at -20°C until extraction and assay, as described above.
Sources of Hypothalamic, Pituitary, and Gastrointestinal Hormones. The following peptides were used for testing crossreactivity in the radioimmunoassay: hpGRF(1-44)NH2 and ovine corticotropin-releasing factor (CRF) (Bachem dure described above. The dilution required to decrease the B/F ratio to <1 was 1:20,000 for both antisera, and this final dilution was used in the radioimmunoassay system for both peptides. The apparent Ka was 3.3 x 10-12 for hpGRF(1-44)NH2 and 7.7 x 10-11 for rhGRF(1-43)OH (30 releasing hormone, SRIF, luteinizing hormone-releasing hormone, corticotropin, p-endorphin, [Met] enkephalin, dynorphin, rat GH, vasoactive intestinal peptide, gastric inhibitory polypeptide, secretin, PHI-27, glucagon, and insulin over a range of 0.20 fmol to 0.02 nM per tube. The intra-and interassay coefficients of variation were 3.63 ± 2.16% (r = 0.9313) and 9.286 ± 3.02% (r = 0.9646), respectively, for hpGRF(1-44)NH2 and 2.12 ± 0.86% (r = 0.9832) and 9.68 ± 1.8% (r = 0.9436), respectively, for rhGRF(1-43)OH.
Hypothalamic GRF-Like Immunoreactivity. Water extracts of hypothalami from various species were tested in our radioimmunoassay systems for GRF-like immunoreactivity. Tissue extracts from human hypothalami produced a parallel dilution curve with hpGRF(1-44)NH2 antigen (Fig. 3) . The appearance of parallelism was confirmed by logit log transformation of the data and comparison of the resultant regression lines by analysis by the F test (31, 32) . The mean GRFlike immunoreactivity in human hypothalami was 3.6 ± 0.2 fmol per mg wet weight of tissue. No crossreactivity was seen with bovine, ovifle, guinea pig, mouse, and rat hypothalamni and hpGRF(1-44)NH2 antiserum (Fig. 5) . Tissue extracts from rat hypothalami produced parallel dilution curves with rhGRF(1-43)OH antigen (Fig. 4) , and parallelism was further confirmed by the same method described above for hpGRF (1-44)NH2 (31, 32) . The mean GRF-like immunoreactivity level in rat hypothalami was 11.1 ± 5.5 fmol per mg wet weight of tissue. No crossreactivity was seen with human, bovine, ovine, guinea pig, and mouse hypothalami and rhGRF(1-43)OH antiserum (Fig. 5) .
Age-Related Levels of rhGRF Content. The age, body weight, and mean hypothalamic GRF content of male rats of different ages is summarized in Table 1 and Fig. 6 . There was a 6-fold increase in hypothalamic GRF content as rats aged from 2 to 16 weeks, and there was a linear correlation between increasing body weight and GRF content. The hypothalamic GRF content at 16 weeks of age is less than the amount reported for the rat hypothalamus in Fig. 5 . The discrepancy in these results is not due to differences in strain or sex but may be related to the differences in breeding conditions of the two groups of rats.
DISCUSSION
The recent isolation, characterization, and subsequent synthesis of hpGRF(1-44)NH2 and rhGRF(1-43)OH has enabled us to develop highly sensitive and specific polyclonal antibodies to these peptides. A noteworthy feature of our production of antiserum to both peptides is the method of immunization of the rabbits. GRF is a weak immunogen, as evidenced by many previously unsuccessful attempts to produce an antibody by the conventional intramuscular method. By injecting these peptides directly into the spleen, we were able to rapidly produce antibodies to both peptides with the following characteristics: high sensitivity (0.2-0.5 fmol per tube for hpGRF(1-44)NH2 and 0.5-1.0 fmol per tube for rhGRF(1-43)OH), good precision, and high specificity as shown by either little or no crossreactivity with all other available neuropeptides as well as the gastrointestinal peptides of the glucagon-secretin family, which share a close structural homology with GRF (18, (23) (24) (25) . In addition, the parallelism with standard and hypothalamic tissue is excellent for both antisera. The lack of hypothalamic GRF-like immunoreactivity in a variety of other species with each of 20 2 30.00 ± 3.67 1.12 ± 0.14 20 4 90.22 ± 1.23 1.71 ± 0.20 15 8 248.33 ± 2.55 4.58 ± 0.42 8 16 440.00 ± 3.10 6.14 ± 0.31 the antibodies further supports the specificity of our antisera.
The lack of crossreactivity between hpGRF(1-44)NH2 antiserum and bovine and ovine hypothalamic GRF, which share a close structural homology with hpGRF(1-44)NH2, is due to the fact that our antiserum is directed against the COOH-terminal portion of hpGRF(1-44)NH2, the region of greatest differences in amino acid sequence. The recent documentation of structural identity between hpGRF(1-44)NH2 and human hypothalamic GRF (refs. 12 and 20; *) indicates that our antiserum raised to hpGRF(1-44)NH2 is specific for human GRF. The discrepancy in the level of hypothalamic GRF in the human and rat, as shown in Fig. 5 , may represent species differences or may be secondary to degradation of the human GRF prior to autopsy.
Immunocytochemical data reported from our laboratoryt4 using our antiserum to rhGRF indicate that rhGRF is primarily located in the arcuate nucleus with lesser amounts in the ventromedial and dorsomedial nuclei. These results confirm previous studies demonstrating that the arcuate and ventromedial nuclei are the major sites of GRF production (2-4). In addition, smaller amounts of GRF were noted in the amygdala and cerebral cortex of the rat.tt Although the physiological significance of GRF in these locations is unknown, it suggests that GRF may function as a neuromodulator integrating neuroendocrine, visceral, and behavioral responses.
Many studies have indicated that high-amplitude GH pulses in rats and humans, mean blood GH secretion in rats, and integrated GH values in humans diminish during aging (33) (34) (35) (36) (37) (38) (39) (40) (41) . The mechanisms involved are unknown but may be due to alterations in the release of GRF and/or SRIF from the hypothalamus. For instance, a decrease in hypothalamic SRIF content has been noted in old rats (34) . However, while injection of antiserum to SRIF in both young and old rats produces a similar increase of plasma GH in both age groups, a higher dose of antiserum causes an increase of plasma GH that is greater in the older than in the younger group (41) . This suggests either an alteration in SRIF secretion by the hypothalamus or increased sensitivity to SRIF with age (41) .
We now report that hypothalamic GRF content in the rat increases with aging. Continuation of this study in our laboratory in rats >16 weeks old will determine whether hypothalamic content continues to increase or levels off at a certain age. Since hypothalamic GRF content is the result of synthesis, degradation, and release of the peptide, it is diffitAudhya, T., Kanie, N., Nakane, T., Manzione, M., Passarelli, J., Russo, M. & Hollander, C. S., Seventh International Congress on Endocrinology, July [1] [2] [3] [4] [5] [6] [7] 1984 , Quebec City, PQ, Canada, abstr. cult to determine the relationship of this observed change in content to diminished GH secretion. Further studies will help decipher the mechanisms involved in the change in hypothalamic SRIF and GRF content as well as the relationship of this change to the alteration in GH secretion with aging.
In conclusion, we have developed highly sensitive and specific radioimmunoassay systems for hpGRF(144)NH2 and rhGRF(1-43)OH that permit detection of femtomole quantities of species-specific GRF-like immunoreactivity in the human and rat hypothalami. Using these antibodies, we have noted previouslyt* that GRF is primarily located in the arcuate nucleus of the hypothalamus, although appreciable quantities are also found in other hypothalamic nuclei, such as the ventromedial nucleus. We also found that hypothalamic GRF content changes with aging. These radioimmunoassay systems will serve as important tools to better understand the physiological role of this peptide in the regulation of GH secretion in man and other animals.
